Kenneth A. Bauer

Q: What Schools Are Affiliated With Kenneth A. Bauer

Kenneth A. Bauer is affiliated with the following schools: University of Limerick, Massachusetts Institute of Technology, Massachusetts General Hospital, University of Cambridge

Kenneth A. Bauer's AcademicInfluence.com Rankings

Kenneth A. Bauer

Philosophy

#6649

World Rank

#9717

Historical Rank

Logic

#3782

World Rank

#4991

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Kenneth A. Bauer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kenneth A. Bauer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Extrapulmonary manifestations of COVID-19 (2020) (1998)
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial (2009) (958)
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. (2002) (752)
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (725)
Activation of coagulation after administration of tumor necrosis factor to normal subjects. (1990) (710)
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) (681)
Inherited Thrombophilia: Part 1 (1996) (637)
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. (2001) (630)
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. (2001) (626)
Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction (1994) (611)
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial (2002) (499)
Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy (2009) (467)
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. (1994) (452)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. (2018) (429)
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. (1987) (424)
Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer (2019) (322)
Inherited Thrombophilia*: Part 2 (1996) (308)
BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study (2005) (306)
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. (1982) (275)
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison (2002) (250)
Factor V Leiden (FV R506Q) in Families with Inherited Antithrombin Deficiency (1996) (244)
Hypercoagulability in centenarians: the paradox of successful aging. (1995) (243)
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery (2008) (237)
Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia (2004) (231)
The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. (1989) (227)
Coagulation Activation Following Estrogen Administration to Postmenopausal Women (1992) (226)
The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. (1993) (222)
Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. (2012) (220)
Pros and cons of new oral anticoagulants. (2013) (216)
Factor IX is activated in vivo by the tissue factor mechanism. (1990) (215)
Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. (1987) (206)
Increased Activation of the Haemostatic System in Men at High Risk of Fatal Coronary Heart Disease (1996) (202)
Guidance for the evaluation and treatment of hereditary and acquired thrombophilia (2016) (202)
Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis (2012) (188)
Respiratory muscle strength in congestive heart failure. (1990) (184)
Comparison of Novel Hemostatic Factors and Conventional Risk Factors for Prediction of Coronary Heart Disease (2000) (182)
Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. (1989) (170)
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) (2008) (167)
Postdischarge thrombosis and hemorrhage in patients with COVID-19 (2020) (162)
Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. (2006) (159)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Thrombin generation in acute promyelocytic leukemia. (1984) (152)
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study) (2013) (138)
DETECTION OF FACTOR X ACTIVATION IN HUMANS (1989) (134)
Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison (2007) (132)
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. (2015) (127)
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. (1990) (127)
Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. (2002) (127)
Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V (1994) (125)
Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. (1987) (123)
The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men (1995) (119)
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH (2012) (117)
Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. (1988) (116)
Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. (1985) (114)
Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. (1989) (108)
The plasma kallikrein–kinin system and risk of cardiovascular disease in men (2007) (104)
The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. (1997) (103)
New Anticoagulants: Anti IIa vs Anti Xa—Is One Better? (2006) (102)
Activation of the Coagulant Pathway in Cigarette Smokers (1998) (100)
Detection of protein C activation in humans. (1984) (96)
Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. (1983) (96)
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa (2011) (95)
In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. (1996) (95)
Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects (2001) (93)
Molecular heterogeneity of inherited antithrombin III deficiency. (1983) (92)
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway (2004) (92)
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events (2005) (92)
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. (1994) (92)
Low Prevalence of the Factor V Leiden Mutation Among “Severe” Hemophiliacs with a “Milder” Bleeding Diathesis (1995) (89)
Venous thrombosis in the elderly: more questions than answers. (2007) (88)
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. (1995) (86)
Reversal of antithrombotic agents (2012) (86)
Hormonal factors and risk of recurrent venous thrombosis: the Prevention of Recurrent Venous Thromboembolism trial (2006) (84)
Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C‐deficient family (2004) (83)
Role of antithrombin III as a regulator of in vivo coagulation. (1991) (82)
D‐dimer, factor VIII coagulant activity, low‐intensity warfarin and the risk of recurrent venous thromboembolism (2006) (81)
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. (1990) (81)
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. (2019) (80)
Activation of Clotting Factors XI and IX in Patients With Acute Myocardial Infarction (2000) (78)
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies (2007) (77)
Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. (2004) (74)
Laboratory markers of coagulation activation. (1993) (71)
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. (1993) (70)
Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels. (1992) (70)
Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19 (2021) (69)
Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. (1983) (69)
Recombinant factor VIIa for the treatment of congenital factor VII deficiency. (2000) (68)
EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. (2005) (66)
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. (1992) (66)
Thrombogenic potential of human coronary atherosclerotic plaques. (2001) (65)
Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease (1992) (63)
Molecular analysis of Polish patients with factor VII deficiency. (1994) (61)
Fondaparinux sodium: a selective inhibitor of factor Xa. (2001) (60)
Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration (2003) (60)
Coagulation activation and long-term outcome in acute coronary syndromes. (2003) (60)
Hypercoagulability: too many tests, too much conflicting data. (2002) (59)
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate (1991) (59)
Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter. (1997) (58)
Acute aortic thrombosis in antithrombin III deficiency. (1981) (58)
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. (2006) (57)
Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease (2004) (57)
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. (1994) (56)
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
Management of Patients with Hereditary Defects Predisposing to Thrombosis Including Pregnant Women (1995) (54)
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. (1997) (54)
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. (2003) (51)
Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. (2007) (49)
Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID‐19 (2020) (49)
Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. (2018) (49)
Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. (1993) (48)
Fondaparinux, the first selective factor Xa inhibitor (2003) (48)
Treatment of factor VII deficiency with recombinant factor VIIa. (1996) (48)
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures (2003) (48)
Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S. (1987) (47)
Activation markers of coagulation. (1994) (45)
A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. (1992) (45)
Risk of Intracranial Hemorrhage in Ground‐level Fall With Antiplatelet or Anticoagulant Agents (2017) (44)
Measures to assess the prognostic ability of the stratified Cox proportional hazards model (2009) (44)
Heparin induced thrombocytopenia antibodies in Covid‐19 (2020) (44)
Management of thrombophilia (2003) (43)
A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule. (1996) (43)
Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements. (1991) (43)
A functional haplotype in the 5′ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease (2003) (42)
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. (2002) (42)
Coagulation activation and long-term outcome in acute coronary syndromes Running title: Coagulation activation and long-term outcome in CHD Section heading: Clinical observation (2003) (42)
Haemostatic changes that constitute the hypercoagulable state (1991) (40)
Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: A summary of case reports (1995) (40)
Hypercoagulability--a new cofactor in the protein C anticoagulant pathway. (1994) (40)
New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. (2003) (39)
Parenteral Anticoagulants (2008) (38)
A chromogenic assay for activated protein C resistance (1995) (37)
Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency (2016) (37)
Recombinant Nematode Anticoagulant Protein c2, a Novel Inhibitor of Tissue Factor-Factor VIIa Activity, Abrogates Endotoxin-Induced Coagulation in Chimpanzees (2002) (36)
Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter. (1998) (36)
Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. (1995) (36)
Targeted Anti-Anticoagulants. (2015) (35)
Coumarin-induced skin necrosis. (1993) (35)
L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. (1983) (34)
Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency (2013) (34)
Initiation of a Multidisciplinary, Rapid Response Team to Massive and Submassive Pulmonary Embolism. (2017) (32)
Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review (2010) (32)
Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency. (2004) (31)
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. (1993) (31)
The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. (2014) (31)
Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces. (1985) (31)
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency (1993) (30)
Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. (1999) (29)
FVII, FVIIa, and Downstream Markers of Extrinsic Pathway Activation Differ by EPCR Ser219Gly Variant in Healthy Men (2009) (29)
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). (2008) (28)
Activation of the Factor VII-Tissue Factor Pathway (1997) (28)
Thrombophilias in pregnancy. (2011) (28)
Thrombin generation in non-cardioembolic stroke subtypes (2004) (27)
The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. (2010) (27)
Expression and characterization of human antithrombin III synthesized in mammalian cells. (1987) (27)
Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery (1994) (27)
Long‐term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d‐dimer results; A cohort study (2019) (27)
Protease inhibitors of human plasma. Antithrombin-III. "The heparin-antithrombin system". (1985) (26)
Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. (2010) (26)
The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency (2004) (26)
Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. (2004) (25)
COMPARISON OF RIVAROXABAN – AN ORAL, DIRECT FACTOR XA INHIBITOR–AND SUBCUTANEOUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT (RECORD4: A PHASE III STUDY) (2010) (25)
Prothrombin Activation Is Increased among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations (2000) (25)
In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris (2000) (25)
Effect of Low‐Intensity Warfarin Anticoagulation on Level of Activity of the Hemostatic System in Patients With Atrial Fibrillation (1993) (23)
The G20210A Prothrombin Polymorphism Is not Associated with Increased Thromboembolic Risk in a Large Protein C Deficient Kindred (2000) (23)
A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency. (2000) (23)
Management of hereditary antithrombin deficiency in pregnancy. (2017) (23)
Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI) (2018) (22)
Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. (1989) (22)
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review (2004) (22)
New markers for in vivo coagulation. (1994) (22)
Factor XIa Induced Activation of the Intrinsic Cascade In Vivo (1996) (21)
Selective inhibition of coagulation factors: advances in antithrombotic therapy. (2002) (21)
Dysfunctional Activated Protein C (PC Cádiz) in a Patient with Thrombotic Disease (1987) (20)
Polymorphisms in the factor VII gene and ischemic stroke in young adults (2010) (20)
Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3'-untranslated region of the prothrombin gene. (1999) (20)
DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. (2020) (20)
Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men (2010) (20)
Role of thrombophilia in deciding on the duration of anticoagulation. (2004) (19)
Determinants of plasma factor VIIa levels in humans. (1995) (19)
F9 Malmö, factor IX and deep vein thrombosis (2009) (19)
Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery (2003) (19)
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4 (2008) (19)
Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation. (1989) (18)
Timing of postpartum enoxaparin administration and severe postpartum hemorrhage (2008) (18)
Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban (2019) (18)
Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. (2020) (17)
Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. (1999) (17)
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery (2008) (17)
Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization. (1991) (16)
Managing Thromboembolic Risk in Patients with Hereditary and Acquired Thrombophilias. (2020) (16)
Stroke Prevention in Atrial Fibrillation in Older Adults: Existing Knowledge Gaps and Areas for Innovation: A Summary of an American Federation for Aging Research Seminar (2013) (16)
Venous thromboembolism in malignancy. (2000) (16)
D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. (2016) (15)
Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur (2003) (15)
Determination of Free Haemoglobin in Serum by an Automated Assay Using 4-Aminophenazone and the Cobas Bio System (1981) (15)
Prothrombin activation fragment assay. (1993) (15)
Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. (2001) (14)
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. (2020) (14)
Changes in Care for Acute Pulmonary Embolism with a Multidisciplinary Pulmonary Embolism Response Team: PE Response Team. (2020) (14)
Current challenges in the management of hemophilia. (2015) (13)
Duration of anticoagulation: applying the guidelines and beyond. (2010) (13)
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. (2021) (13)
Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. (1995) (13)
Development of a radioimmunoassay for quantitating prethrombin 2 in human plasma. (1987) (13)
International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis (2016) (13)
Fondaparinux Combined with Intermittent Pneumatic Compression (IPC) Versus IPC Alone in the Prevention of Venous Thromboembolism after Major Abdominal Surgery: The Randomized APOLLO Study. (2005) (12)
Asymptomatic factor VII deficiency in African Americans. (2006) (12)
Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra) administration in the prevention of venous thromboembolism (VTE) after major orthopedic surgery (2003) (12)
Determinants of plasma factor VIIa levels in humans (1995) (11)
How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. (2014) (11)
Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States (2020) (11)
Trousseau’s Syndrome Revisited: Tissue Factor-Bearing Microparticles in Pancreatic Cancer. (2005) (11)
New insights into hypercoagulable states. (1986) (10)
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery (2003) (10)
A simple, automated functional assay for protein C. (1989) (10)
Automated detection of the factor V Leiden mutation using the LCx microparticle enzyme immunoassay. (1999) (10)
Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study: 121 (2019) (10)
Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. (2002) (10)
Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism. (2011) (9)
Detection of a prethrombotic state (1994) (9)
Hormone replacement therapy and the factor V Leiden mutation. (2002) (9)
Conventional Fibrinolytic Assays for the Evaluation of Patients with Venous Thrombosis: Don’t Bother (2001) (8)
Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision analysis. (2009) (8)
Targeted inhibition of coagulation: oral agents show promise in phase III trials (2007) (8)
Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. (1985) (8)
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. (2013) (7)
ARP1 interacts with the 5′ flanking region of the coagulation factor VII gene (2003) (7)
Does a prethrombotic state exist? If so, what is it? (1992) (7)
Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation (1999) (7)
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism (2002) (6)
Interaction of factor V Leiden with inherited anti-thrombin deficiency (1995) (6)
Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay. (2001) (6)
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. (2013) (6)
Case records of the Massachusetts General Hospital. Weekly Clinicopathological Exercises. Case 12-1996. An 18-year-old woman with hepatomegaly and ascites. (1996) (6)
New oral anticoagulants in development: potential for improved safety profiles. (2010) (6)
Use of thromboelastography in the management of a patient with acquired von Willebrand disease undergoing cardiac bypass surgery (2018) (5)
F 9 Malmö , factor IX and deep vein thrombosis (5)
Does Inflammatory Proteolytic Activity Contribute to the Increased Factor IX Activation Peptide in Men at High Risk of Coronary Heart Disease? A Preliminary Study (2002) (5)
O1067 INFLUENCE OF THE DURATION OF FONDAPARINUX PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY (2004) (4)
How Effective and Safe Is Factor XI Inhibition in Preventing Venous Thrombosis? (2020) (4)
New anticoagulants. (2006) (4)
Practice Guidelines (8th Edition) Clinical of Chest Physicians Evidence-Based Parenteral Anticoagulants: American College (2008) (3)
The role of other hemostatic factors in predicting arterial thrombotic events. (2006) (3)
Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity (2002) (3)
Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor: Pooled results of two phase Iib clinical trials. (2005) (3)
Increased incidence of neoplasia with persistent activation of the of the digestive tract in men coagulant pathway (2004) (3)
CHAPTER 37 – The Level of Activity of the Hemostatic System, the Rate of Embolic Stroke, and Age: Is There a Correlation? (1995) (3)
New anticoagulants (2008) (2)
Low intensity warfarin: is it clinically useful in venous thromboembolism management? (2004) (2)
Functional tissue factor in blood (2005) (2)
Thrombophilia: Clinical and Laboratory Assessment and Management (2019) (2)
Malmö , factor IX and deep vein thrombosis (2009) (2)
Thrombolytic therapy in acute venous thromboembolism. (2020) (2)
Determinants of coagulation activation in humans. (1996) (2)
How to detect activated coagulation (1996) (2)
Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series. (2022) (2)
Pentasaccharide (fondaparinux, Arixtra) versus enoxaparin for the prevention of venous thromboembolism (VTE) in major orthopedic surgery: subgroup analyses of efficacy (2003) (2)
Effect on efficacy and safety of the timing of the first pentasaccharide administration in the prevention of venous thromboembolism (2001) (1)
Coronary Heart Disease / Myocardial Infarction Diminished Vascular Response to Inhibition of Endothelium-Derived Nitric Oxide and Enhanced Vasoconstriction to Exogenously Administered Endothelin-1 in Clinically Healthy Smokers (2005) (1)
Subject Index, Vol. 26 (suppl 1), 1996 (1996) (1)
The challenge of hospital-related thrombosis. (2017) (1)
TFPI and venous thrombosis (2003) (1)
Activation markers of coagulation. (1999) (1)
Overview and research opportunities (1992) (1)
Progestin-Only Contraceptives and the Risk of Venous Thromboembolism: Systematic Review and Meta-Analysis, (2011) (1)
Aspirin thromboprophylaxis in joint replacement surgery (2022) (1)
Professor Stanislaw Lopaciuk (1935–2003) (2004) (1)
Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study) (2018) (1)
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. (2002) (1)
Hemostatic markers and prognosis in ischemic heart disease. (2001) (0)
ACTIVATION OF EXTRINSIC COAGULATION PATHWAY IN HEALTH THAT INDEPENDENTLY PREDICTS LATER ONSET OF HEART DISEASE, IS MODIFIED BY GENOTYPE (2008) (0)
O1062 ELASTIC STOCKINGS DO NOT INFLUENCE SUPERIOR EFFICACY OF FONDAPARINUX OVER ENOXAPARIN FOR THROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY (2004) (0)
Efficacy of Fondaparinux for Thromboprophylaxis in High-risk Patients Undergoing Hip Fracture Surger (2003) (0)
Abstract 72: Procedural and Long Term Safety of PFO Closure in Cryptogenic Stroke: Insights from the RESPECT Trial (2017) (0)
A Balancing Act. (2020) (0)
Timing and Safety of Postpartum Enoxparin. (2006) (0)
O1063 EFFECT ON EFFICACY AND SAFETY OF THE TIMING OF THE FIRST FONDAPARINUX ADMINISTRATION FOR THE THROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY (2004) (0)
O1064 MANAGEMENT OF ORTHOPEDIC SURGERY PATIENTS IN NORTH AMERICA, EUROPE AND OTHER COUNTRIES: LESSONS FROM THE FONDAPARINUX DATABASE (2004) (0)
Proceedings of the National Heart, Lung, and Blood Institute Workshop on Hemostasis, Thrombosis, and Cardiovascular Diseases. Overview and research opportunities. (1992) (0)
Enoxaparin thrombophylaxis did not reduce mortality in acutely ill medical patients (2012) (0)
Site in the Factor VII Promoter Severe Factor VII Deficiency Due to a Mutation Disrupting an Sp1 Binding (2010) (0)
myocardial infarction without altering von Willebrand Factor multimer size The thrombospondin-1 N700S polymorphism is associated with early (2013) (0)
Fibrinogen Ledyard (Adrg,, + Cys): Biochemical and Physiologic Characterization (2003) (0)
Molecular genetics of inherited factor VII deficiencies (1999) (0)
Low Molecular Weight Heparin to Achieve Live Birth Following Unexplained Pregnancy Loss: A Meta-Analysis. (2009) (0)
O3382 THE USE OF REGIONAL ANESTHESIA IN MAJOR ORTHOPAEDIC SURGERY (2004) (0)
Title Page / Table of Contents, Vol. 26, Supplement 1, 1996 (1996) (0)
Should You Treat This Acutely Ill Medical Inpatient With Venous Thromboembolism Chemoprophylaxis? (2020) (0)
The Biologic Impact of Hereditary Defects that Cause Thrombosis (1991) (0)
Abstract: 522 FVII, FVIIA AND DOWNSTREAM MARKERS OF EXTRINSIC PATHWAY ACTIVATION DIFFER BY EPCR SER219GLY VARIANT IN HEALTHY MEN (2009) (0)
Transient decrease of thrombin generation during hirudin treatment in patients with acute coronary syndromes (1998) (0)
THROMBOPROPHYLAXIS AFTER ORTHOPAEDIC SURGERY WITH BAY 59-7939–AN ORAL, DIRECT FACTOR XA INHIBITOR: (2008) (0)
syndromes Coagulation activation and long-term outcome in acute coronary (2013) (0)
Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders. (2002) (0)
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII) (2008) (0)
Hypercoagulable states (2005) (0)
Future Prospects in the Management of Acute Coronary Syndrome and Thrombosis (2006) (0)
Thrombophilia evaluation: the value of testing relatives. (2010) (0)
In Memoriam: Professor Robert Daniel Rosenberg, 1937-2020. (2020) (0)
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism—ATVB In Focus (2005) (0)
The clinical spectrum of heterozygous protein C deficiency in a large New (2011) (0)
ANTITHROMBIN III CONCENTRATE (AT-III) FOR PROPHYLAXIS ANDTREATMENT OF CONGENITAL AND ACQUIREDAT-III DEFCIENCY (1987) (0)
Negative D-dimer Not Sufficient to Stop Anticoagulation in Men (2019) (0)
The Thrombospondin-1 N700S Polymorphism Does Not Alter von Willebrand Factor Multimer Size in Patients Suffering an Acute Myocardial Infarction. (2005) (0)
Report of the 2008 ASHP Task Force on Science. (2009) (0)
Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS) (2003) (0)
O1066 FONDAPARINUX IS SUPERIOR TO ENOXAPARIN FOR THROMBOPROPHYLAXIS IN ORTHOPEDIC SURGERY IRRESPECTIVE OF PATIENTS OR SURGERY CHARACTERISTICS (2004) (0)
[Treatment and prevention of thrombotic episodes with hereditary thrombophilia]. (1997) (0)
Fondaparinux. (2020) (0)
Extrapulmonary manifestations of COVID-19 (2020) (0)
Abnormal Factor Vil Coagulant Antigen in Patients with Renal Dysfunction and in Those with Disseminated Intravascular Coagulation (2013) (0)
Diagnosis of myocardial disease or stroke using factor ix activation peptide (1999) (0)
NONANTICOAGULANT INTERVENTIONS IN Thrombolytic therapy in acute venous thromboembolism (2020) (0)
Congenital thrombophilia and venous disease (2006) (0)
Development of Venous Thromboembolic Events in Cancer Patients with Elevated Levels of Tissue Factor-Bearing Microparticles (2008) (0)
CP-ACPJ210009 1..12 (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kenneth A. Bauer?

Kenneth A. Bauer is affiliated with the following schools:

Kenneth A. Bauer's Academic­Influence.com Rankings

Why Is Kenneth A. Bauer Influential?

Kenneth A. Bauer's Published Works

Published Works

What Schools Are Affiliated With Kenneth A. Bauer?

Kenneth A. Bauer's AcademicInfluence.com Rankings